Relapsed or refractory diffuse large B-cell lymphoma refers to the aggressiveness of DLBCL that has not responded to initial treatment or has returned after achieving remission. Key products under relapsed or refractory diffuse large B-cell lymphoma market include monoclonal antibodies, immunomodulators and kinase inhibitors used to treat lymphoma with complex medical needs. The global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing Incidence Rates of Lymphoma
The rising incidence rates of lymphoma across the globe is a major Global Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Size. According to the National Cancer Institute, in 2022 there will be around 86,720 new cases of non-Hodgkin lymphoma diagnosed in the US. The increasing aging population base as well as sedentary lifestyle trends are some of the key factors fueling lymphoma incidence. With relapse rates over 60% in some DLBCL patients, the market for relapsed or refractory diffuse large B-cell lymphoma therapeutics is expected to witness significant growth over the forecast period backed by the high unmet need.
Segment Analysis
The global relapsed or refractory diffuse large B-cell lymphoma market is dominated by the chemotherapy sub segment. Chemotherapy is the standard treatment for relapsed or refractory diffuse large B-cell lymphoma patients. Chemotherapeutic drugs like rituximab, bendamustine, etoposide and dexamethasone are commonly prescribed in chemotherapy. Their widespread usage and proven effectiveness in treating the condition has made chemotherapy the preferred treatment sub segment.
Key Takeaways
The global relapsed or refractory diffuse large B-cell lymphoma market is expected to witness high growth in the coming years.
Regional analysis: The North American region currently dominates the global relapsed or refractory diffuse large B-cell lymphoma market. Higher awareness about treatment options and advanced healthcare infrastructure is driving market growth in the region. Additionally, presence of leading market players are contributing to North America's large share. However, the Asia Pacific region is expected to present most lucrative opportunities during the forecast period owing to rising healthcare expenditure and improving access to novel therapies in countries like China and India.
Key players: Key players operating in the relapsed or refractory diffuse large B-cell lymphoma market are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. Sharp Corp. and LG hold major market share for chemotherapy drugs segment. Samsung and Hitachi are focusing on cell therapies and CAR T-cell therapies to gain foothold in the lucrative market. Panasonic has recently received approval for its CD19 targeted CAR T-cell therapy and is expected to strengthen its position.
Get More Insights On This Topic: https://www.ukwebwire.com/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market-size-share-analysis-2023-2030/
Comments
0 comment